PharVision Advisers’s Oracle ORCL Stock Holding History

PharVision Advisers’s Portfolio ORCL Stock Details ORCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,147	Closed	-$469K	–	755
2025 Q2	$469K	Buy	+2,147	New	+$347K	0.67%	9

Other funds holding ORCL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's ORCL Position: Q3 2025 in Review

PharVision Advisers sold out of Oracle (ORCL) in Q3 2025, closing a stake of 2,147 shares — an estimated $469K sold.

PharVision Advisers first reported a position in ORCL in Q2 2025 and held it in 1 quarter. The position peaked at $469K in Q2 2025. 3,820 funds tracked by Wall St. Rank hold ORCL as of Q3 2025.

PharVision Advisers reported no remaining Oracle position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 2,147 Oracle shares in Q3 2025, an estimated $469K.
PharVision Advisers first reported a position in Oracle in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Oracle position peaked at $469K in Q2 2025.
3,820 funds tracked by Wall St. Rank held Oracle as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.